Average Ratings 0 Ratings
Average Ratings 0 Ratings
Description
BenevolentAI is a pioneering platform that leverages artificial intelligence and scientific technology to enhance drug discovery processes, specifically targeting complex diseases by efficiently processing and interpreting extensive biomedical data to yield actionable insights more swiftly than conventional approaches. By utilizing its unique Benevolent Platform, the company seamlessly integrates both structured and unstructured biomedical information—spanning literature, genomics, clinical data, and multi-omics—into a detailed knowledge graph. This robust framework empowers researchers to analyze biological systems, formulate testable hypotheses, identify new drug targets, and create potential drug candidates with increased confidence and reduced failure rates, ultimately transforming the landscape of medicine development. With its innovative approach, BenevolentAI stands at the forefront of a new era in the pharmaceutical industry.
Description
By leveraging visual analytics through TIBCO Spotfire®, PerkinElmer Signals Translational offers a comprehensive suite of tools designed to harmonize, manage, search, aggregate, and analyze extensive datasets consistently for translational research, all while ensuring scalability. This platform, driven by TIBCO Spotfire®, supports precision medicine initiatives by providing an unparalleled solution for biomarker discovery and patient stratification. The Linear Mixed Effect App (LME) within Signals Translational empowers researchers to evaluate the influence of various factors on specific phenotypes, allowing for adjustments related to random variables during analysis. Furthermore, it enables the identification of genes significantly affecting cancer stage progression, irrespective of patient origins. Notably, the LME models excel at addressing issues such as missing values and outliers, making them a robust choice for discovering potential biomarkers. Consequently, the integration of these advanced analytics tools enhances the efficacy of translational research in identifying key biomarkers that can lead to more personalized treatment approaches.
API Access
Has API
No
API Access
Has API
No
Integrations
Signals Research Suite
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Pricing Details
No price information available.
Free Trial
No
Free Version
No
Deployment
Web-Based
Yes
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
No
Mac
No
Linux
No
Chromebook
No
Deployment
Web-Based
No
On-Premises
No
iPhone App
No
iPad App
No
Android App
No
Windows
Yes
Mac
Yes
Linux
No
Chromebook
No
Customer Support
Business Hours
Yes
Live Rep (24/7)
No
Online Support
Yes
Customer Support
Business Hours
No
Live Rep (24/7)
No
Online Support
Yes
Types of Training
Training Docs
Yes
Webinars
No
Live Training (Online)
Yes
In Person
No
Types of Training
Training Docs
Yes
Webinars
Yes
Live Training (Online)
Yes
In Person
No
Vendor Details
Company Name
BenevolentAI
Founded
2013
Country
Luxembourg
Website
www.benevolent.com
Vendor Details
Company Name
PerkinElmer
Founded
1937
Country
United States
Website
perkinelmerinformatics.com/products/clinical-translational/signals-translational/